See every side of every news story

Published 11 days ago • loading... • Updated 11 days ago

FDA gives RMAT status to Vigil immunotherapy for ovarian cancer

Summary by rarecancernews.com

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Gradalis’ experimental immunotherapy platform Vigil (Gemogenovatucel-T) as a potential treatment for advanced ovarian cancer. RMAT status is given to cellular and engineered therapies showing an early potential in clinical testing to improve care for serious conditions. It aims to help speed the development of important new therap…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

rarecancernews.com

FDA gives RMAT status to Vigil immunotherapy for ovarian cancer

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Gradalis’ experimental immunotherapy platform Vigil (Gemogenovatucel-T) as a potential treatment for advanced ovarian cancer. RMAT status is given to cellular and engineered therapies showing an early potential in clinical testing to improve care for serious conditions. It aims to help speed the development of important new therap…

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated10 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

rarecancernews.com broke the news in 11 days ago on Wednesday, February 12, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics